The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CAR T-Cell-Based Drug Market Research Report 2024
Synopsis
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Global CAR T-Cell-Based Drug market is projected to reach US$ 19190 million in 2029, increasing from US$ 2806 million in 2022, with the CAGR of 29.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CAR T-Cell-Based Drug market research.
The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient's T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CAR T-Cell-Based Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Segment by Type
CD19-targeted
BCMA-targeted
Segment by Application
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CAR T-Cell-Based Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Global CAR T-Cell-Based Drug market is projected to reach US$ 19190 million in 2029, increasing from US$ 2806 million in 2022, with the CAGR of 29.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CAR T-Cell-Based Drug market research.
The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient's T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CAR T-Cell-Based Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Segment by Type
CD19-targeted
BCMA-targeted
Segment by Application
Lymphoma
Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CAR T-Cell-Based Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR T-Cell-Based Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CD19-targeted
1.2.3 BCMA-targeted
1.3 Market by Application
1.3.1 Global CAR T-Cell-Based Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell-Based Drug Market Perspective (2018-2029)
2.2 CAR T-Cell-Based Drug Growth Trends by Region
2.2.1 Global CAR T-Cell-Based Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 CAR T-Cell-Based Drug Historic Market Size by Region (2018-2023)
2.2.3 CAR T-Cell-Based Drug Forecasted Market Size by Region (2024-2029)
2.3 CAR T-Cell-Based Drug Market Dynamics
2.3.1 CAR T-Cell-Based Drug Industry Trends
2.3.2 CAR T-Cell-Based Drug Market Drivers
2.3.3 CAR T-Cell-Based Drug Market Challenges
2.3.4 CAR T-Cell-Based Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell-Based Drug Players by Revenue
3.1.1 Global Top CAR T-Cell-Based Drug Players by Revenue (2018-2023)
3.1.2 Global CAR T-Cell-Based Drug Revenue Market Share by Players (2018-2023)
3.2 Global CAR T-Cell-Based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR T-Cell-Based Drug Revenue
3.4 Global CAR T-Cell-Based Drug Market Concentration Ratio
3.4.1 Global CAR T-Cell-Based Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell-Based Drug Revenue in 2022
3.5 CAR T-Cell-Based Drug Key Players Head office and Area Served
3.6 Key Players CAR T-Cell-Based Drug Product Solution and Service
3.7 Date of Enter into CAR T-Cell-Based Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-Cell-Based Drug Breakdown Data by Type
4.1 Global CAR T-Cell-Based Drug Historic Market Size by Type (2018-2023)
4.2 Global CAR T-Cell-Based Drug Forecasted Market Size by Type (2024-2029)
5 CAR T-Cell-Based Drug Breakdown Data by Application
5.1 Global CAR T-Cell-Based Drug Historic Market Size by Application (2018-2023)
5.2 Global CAR T-Cell-Based Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America CAR T-Cell-Based Drug Market Size (2018-2029)
6.2 North America CAR T-Cell-Based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CAR T-Cell-Based Drug Market Size by Country (2018-2023)
6.4 North America CAR T-Cell-Based Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR T-Cell-Based Drug Market Size (2018-2029)
7.2 Europe CAR T-Cell-Based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CAR T-Cell-Based Drug Market Size by Country (2018-2023)
7.4 Europe CAR T-Cell-Based Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell-Based Drug Market Size (2018-2029)
8.2 Asia-Pacific CAR T-Cell-Based Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CAR T-Cell-Based Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific CAR T-Cell-Based Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR T-Cell-Based Drug Market Size (2018-2029)
9.2 Latin America CAR T-Cell-Based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CAR T-Cell-Based Drug Market Size by Country (2018-2023)
9.4 Latin America CAR T-Cell-Based Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell-Based Drug Market Size (2018-2029)
10.2 Middle East & Africa CAR T-Cell-Based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa CAR T-Cell-Based Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis CAR T-Cell-Based Drug Introduction
11.1.4 Novartis Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.1.5 Novartis Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences CAR T-Cell-Based Drug Introduction
11.2.4 Gilead Sciences Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Introduction
11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 J & J
11.4.1 J & J Company Detail
11.4.2 J & J Business Overview
11.4.3 J & J CAR T-Cell-Based Drug Introduction
11.4.4 J & J Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.4.5 J & J Recent Development
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Detail
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics CAR T-Cell-Based Drug Introduction
11.5.4 JW Therapeutics Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.5.5 JW Therapeutics Recent Development
11.6 FOSUNKite
11.6.1 FOSUNKite Company Detail
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite CAR T-Cell-Based Drug Introduction
11.6.4 FOSUNKite Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.6.5 FOSUNKite Recent Development
11.7 CARsgen Therapeutics
11.7.1 CARsgen Therapeutics Company Detail
11.7.2 CARsgen Therapeutics Business Overview
11.7.3 CARsgen Therapeutics CAR T-Cell-Based Drug Introduction
11.7.4 CARsgen Therapeutics Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.7.5 CARsgen Therapeutics Recent Development
11.8 Autolus Therapeutics
11.8.1 Autolus Therapeutics Company Detail
11.8.2 Autolus Therapeutics Business Overview
11.8.3 Autolus Therapeutics CAR T-Cell-Based Drug Introduction
11.8.4 Autolus Therapeutics Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.8.5 Autolus Therapeutics Recent Development
11.9 Sorrento Therapeutics
11.9.1 Sorrento Therapeutics Company Detail
11.9.2 Sorrento Therapeutics Business Overview
11.9.3 Sorrento Therapeutics CAR T-Cell-Based Drug Introduction
11.9.4 Sorrento Therapeutics Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.9.5 Sorrento Therapeutics Recent Development
11.10 Mustang Bio
11.10.1 Mustang Bio Company Detail
11.10.2 Mustang Bio Business Overview
11.10.3 Mustang Bio CAR T-Cell-Based Drug Introduction
11.10.4 Mustang Bio Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.10.5 Mustang Bio Recent Development
11.11 Bluebird Bio
11.11.1 Bluebird Bio Company Detail
11.11.2 Bluebird Bio Business Overview
11.11.3 Bluebird Bio CAR T-Cell-Based Drug Introduction
11.11.4 Bluebird Bio Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.11.5 Bluebird Bio Recent Development
11.12 Cellectis
11.12.1 Cellectis Company Detail
11.12.2 Cellectis Business Overview
11.12.3 Cellectis CAR T-Cell-Based Drug Introduction
11.12.4 Cellectis Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.12.5 Cellectis Recent Development
11.13 Allogene Therapeutics
11.13.1 Allogene Therapeutics Company Detail
11.13.2 Allogene Therapeutics Business Overview
11.13.3 Allogene Therapeutics CAR T-Cell-Based Drug Introduction
11.13.4 Allogene Therapeutics Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.13.5 Allogene Therapeutics Recent Development
11.14 Celyad
11.14.1 Celyad Company Detail
11.14.2 Celyad Business Overview
11.14.3 Celyad CAR T-Cell-Based Drug Introduction
11.14.4 Celyad Revenue in CAR T-Cell-Based Drug Business (2018-2023)
11.14.5 Celyad Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
